CTChristopher Tallman

Christopher Tallman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher Tallman has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Aquablation outcomes for the U.S. cohort of men with LUTS due to BPH in large prostates (80–150 cc)

    by Faysal A. Yafi, Christopher T. Tallman, Melvin L. Seard, Mark L. Jordan

    Between September and December 2017, 82 men with moderate-to-severe lower urinary tract symptoms due to benign prostatic hyperplasia LUTS/BPH and prostate volume of 80–150 cc underwent Aquablation in a prospective multicenter clinical trial in the United States. Baseline patient and clinical demographics and standardized postoperative parameters were collected and tabulated in a central independently monitored database. Adverse events through 3 months were adjudicated by an independent clinical events committee. Mean pre-treatment prostate volume was 108 ± 21.1 cc. Mean operative time was 38.2 ± 14.4 min and mean Aquablation resection time was 7.7 ± 3.3 min. Additional electrocautery for hemostasis was not needed in any patient following Aquablation. The average length of stay following the procedure was 1.6 ± 1.0 days. Mean pre- and 3 months post-treatment IPSS scores were 23.7 ± 6.4 and 7.1 ± 5.1, –16.6, p < 0.01. Mean pre- and 3 months post-treatment Qmax were 9.2 ± 3.3 ml/s and 19.5 ± 13 ml/s, + 10.8 ml/s, p < 0.01. Mean pre- and 3 months post-treatment post-void residuals were 120.6 ± 119.1 cc and 50.6 ± 61.6 cc, –72.0 cc, p < 0.01. The observed Clavien-Dindo grade 2 or higher event rate at 3 months was 34.1%. Aquablation is a safe and effective treatment option for men with large prostates (80–150 cc) suffering from LUTS/BPH.


  • Functional Recovery, Oncologic Outcomes and Postoperative Complications after Robot-Assisted Radical Prostatectomy: An Evidence-Based Analysis Comparing the Retzius Sparing and Standard Approaches

    by Mani Menon, Deepansh Dalela, Marcus Jamil, Mireya Diaz, Christopher Tallman, Firas Abdollah, Akshay Sood, Linda Lehtola, David Miller, Wooju Jeong

    We report a 1-year update of functional urinary and sexual recovery, oncologic outcomes and postoperative complications in patients who completed a randomized controlled trial comparing posterior (Retzius sparing) with anterior robot-assisted radical prostatectomy. A total of 120 patients with clinically low-intermediate risk prostate cancer were randomized to undergo robot-assisted radical prostatectomy via the posterior and anterior approach in 60 each. Surgery was performed by a single surgical team at an academic institution. An independent third party ascertained urinary and sexual function outcomes preoperatively, and 3, 6 and 12 months after surgery. Oncologic outcomes consisted of positive surgical margins and biochemical recurrence-free survival. Biochemical recurrence was defined as 2 postoperative prostate specific antigen values of 0.2 ng/ml or greater. Median age of the cohort was 61 years and median followup was 12 months. At 12 months in the anterior vs posterior prostatectomy groups there were no statistically significant differences in the urinary continence rate (0 to 1 security pad per day in 93.3% vs 98.3%, p = 0.09), 24-hour pad weight (median 12 vs 7.5 gm, p = 0.3), erection sufficient for intercourse (69.2% vs 86.5%) or postoperative Sexual Health Inventory for Men score 17 or greater (44.6% vs 44.1%). In the posterior vs anterior prostatectomy groups a nonfocal positive surgical margin was found in 11.7% vs 8.3%, biochemical recurrence-free survival probability was 0.84 vs 0.93 and postoperative complications developed in 18.3% vs 11.7%. Among patients with clinically low-intermediate risk prostate cancer randomized to anterior (Menon) or posterior (Bocciardi) approach robot-assisted radical prostatectomy the differences in urinary continence seen at 3 months were muted at the 12-month followup. Sexual function recovery, postoperative complication and biochemical recurrence rates were comparable 1 year postoperatively.


  • Health-related Quality of Life Outcomes After Robot-assisted and Open Radical Cystectomy Using a Validated Bladder-specific Instrument: A Multi-institutional Study

    by Ahmed A. Aboumohamed, Syed Johar Raza, Ali Al-Daghmin, Christopher Tallman, Terrance Creighton, Heather Crossley, Stephen Dailey, Aabroo Khan, Rakeeba Din, Diana Mehedint, et al.


  • Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection

    by Christopher P. Filson, Jeffrey S. Montgomery, Stephen M. Dailey, Heather S. Crossley, Heidi Lentz, Christopher T. Tallman, Chang He, Alon Z. Weizer


  • Matched Comparison of Robotic-assisted and Open Radical Cystectomy

    by Nicholas R. Styn, Jeffery S. Montgomery, David P. Wood, Khaled S. Hafez, Cheryl T. Lee, Christopher Tallman, Chang He, Heather Crossley, Brent K. Hollenbeck, Alon Z. Weizer


  • Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression

    by Nagireddy Putluri, Ali Shojaie, Vihas T. Vasu, Shaiju K. Vareed, Srilatha Nalluri, Vasanta Putluri, Gagan Singh Thangjam, Katrin Panzitt, Christopher T. Tallman, Charles Butler, et al.

    Although alterations in xenobiotic metabolism are considered causal in the development of bladder cancer, the precise mechanisms involved are poorly understood. In this study, we used high-throughput mass spectrometry to measure over 2,000 compounds in 58 clinical specimens, identifying 35 metabolites which exhibited significant changes in bladder cancer. This metabolic signature distinguished both normal and benign bladder from bladder cancer. Exploratory analyses of this metabolomic signature in urine showed promise in distinguishing bladder cancer from controls and also nonmuscle from muscle-invasive bladder cancer. Subsequent enrichment-based bioprocess mapping revealed alterations in phase I/II metabolism and suggested a possible role for DNA methylation in perturbing xenobiotic metabolism in bladder cancer. In particular, we validated tumor-associated hypermethylation in the cytochrome P450 1A1 (CYP1A1) and cytochrome P450 1B1 (CYP1B1) promoters of bladder cancer tissues by bisulfite sequence analysis and methylation-specific PCR and also by in vitro treatment of T-24 bladder cancer cell line with the DNA demethylating agent 5-aza-2′-deoxycytidine. Furthermore, we showed that expression of CYP1A1 and CYP1B1 was reduced significantly in an independent cohort of bladder cancer specimens compared with matched benign adjacent tissues. In summary, our findings identified candidate diagnostic and prognostic markers and highlighted mechanisms associated with the silencing of xenobiotic metabolism. The metabolomic signature we describe offers potential as a urinary biomarker for early detection and staging of bladder cancer, highlighting the utility of evaluating metabolomic profiles of cancer to gain insights into bioprocesses perturbed during tumor development and progression. Cancer Res; 71(24); 7376–86. ©2011 AACR.


  • Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle‐invasive bladder cancer

    by Ajjai S. Alva, Christopher T. Tallman, Chang He, Maha H. Hussain, Khaled Hafez, James E. Montie, David C. Smith, Alon Z. Weizer, David Wood, Cheryl T. Lee

    BACKGROUND: Cystectomy delay >90 days after a diagnosis of muscle‐invasive bladder cancer (MIBC) adversely affects pathologic stage and survival outcomes in patients who undergo primary surgery. After neoadjuvant chemotherapy (NAC), the impact of the timing of cystectomy delivery on these outcomes is uncertain. Poor communication between urologic and medical oncologists can result in cystectomy delay after systemic treatment. The authors of this report hypothesized that a delay in cystectomy delivery after NAC is associated with adverse survival outcomes. METHODS: An eligible cohort of 153 patients with MIBC received NAC and underwent radical cystectomy between 1990 and 2007. At the authors' institution, the genitourinary team strives to schedule patients for surgery at the time of initial evaluation or after their first chemotherapy cycle. Clinicopathologic characteristics, including timing of cystectomy, chemotherapy delivery, vital status, and reasons for excessive surgical delay, were analyzed retrospectively using an institutional database. A Cox proportional regression model was used to test the association between the timing of cystectomy delivery and survival. RESULTS: The median follow‐up for all patients was 3.6 years. The median time to cystectomy was 16.6 weeks and 6.9 weeks from the first and last day of NAC, respectively. In multivariate analyses, the timing of cystectomy delivery from the termination of NAC did not significantly alter the risk of survival. The most common reason for cystectomy delivery beyond 10 weeks (28 patients; 18%) was procedural scheduling. CONCLUSIONS: Cystectomy delivery within 10 weeks after NAC did not compromise patient survival and, thus, provided a reasonable window for patient recovery and surgical intervention. Cancer 2012;. © 2011 American Cancer Society.


  • Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer

    by Alon Z. Weizer, Christopher Tallman, Jeffrey S. Montgomery

    The purpose of the current review was to evaluate the long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer. A literature search was performed to identify studies documenting long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer. Data from each study were collected using standardized forms that included information on author, date of study, journal, study type, intravesical therapy used, number of patients, length of follow-up, and outcome measures (recurrence, progression, and disease-specific and overall mortality). This information was then tabulated and summarized. Of 420 publications identified, 79 were chosen for data abstraction. The long-term impact of intravesical BCG, mitomycin, epirubicin (with or without maintenance/with or without immediate therapy), and transurethral resection alone demonstrated marginal impact on recurrence. However, BCG with or without maintenance appeared to reduce disease progression over the long term compared to other therapies. Data on mortality associated with intravesical therapy were limited. In general, the literature was limited by inconsistent reporting of outcomes and lack of standardization. Long-term outcomes after intravesical therapy for non-muscle invasive bladder cancer are difficult to asses due to the lack of quality long-term data and inconsistencies in reporting results. It is clear that better long-term data are needed to define the impact of intravesical therapy on the natural history of the disease.


  • Loss of 15-Hydroxyprostaglandin Dehydrogenase Expression Contributes to Bladder Cancer Progression

    by Stephanie Tseng-Rogenski, Jason Gee, Kathleen Woods Ignatoski, Lakshmi P. Kunju, Amanda Bucheit, Hallie J. Kintner, David Morris, Christopher Tallman, Joshua Evron, Christopher G. Wood, et al.


  • Overactive bladder: recognition requires vigilance for symptoms.

    by M. T Rosenberg, D. K Newman, C. T Tallman, S. A Page

    Overactive bladder (OAB) is a prevalent condition in both men and women that imposes significant burdens on the patient and his or her quality of life. Nevertheless, only a small percentage of patients with OAB receive diagnosis and treatment. The identification of OAB is well within the scope of the primary care provider, as it is symptom-based and does not generally require specialized testing. The treatment of OAB relies on behavioral modification and/or pharmacologic options, primarily antimuscarinic therapy. Better identification of OAB symptoms in the primary care setting should reduce the number of patients suffering from untreated OAB.